Ultrarare inflection point: stakeholders argue for biomarker-based approvals - BioCentury
A meeting convened by the Reagan-Udall Foundation for the FDA on qualifying rare disease biomarkers for accelerated approvals could be an inflection point for patients with ultrarare diseases, their families, biotech companies, and FDA.